Compare Amylx Pharmaceuticals Inc (AMLX) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Alliant Energy Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Alliant Energy Corporation trades at $76.4 (market cap $19.73B). The key difference: Alliant Energy Corporation is far larger — about 10× Amylx Pharmaceuticals Inc's market cap, and Alliant Energy Corporation pays a 2.73% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | LNT | |
|---|---|---|
Market Cap | $1.98B | $19.73B |
Sector | Health | Utilities |
52-Week High | $18.70 | $78.03 |
52-Week Low | $7.64 | $61.85 |
Enterprise Value | $1.70B | $31.45B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
LNT trades at $76.40, up 0.92% today, with a bullish technical signal and mixed earnings history including a recent Q1 2026 beat. The company shows steady revenue growth to $4.36B in 2025 and a net margin of 18.58%, supported by a $13.4B investment plan and data center demand. Analysts are split with a 52% buy rating and a $75.67 consensus target, while the stock pays a $0.54 dividend.
Outlook is positive due to strategic investments and sector tailwinds, but risks include rising debt levels and interest rate sensitivity. The stock offers growth and income appeal, though investors should monitor execution on capital expenditures and competitive pressures in the utility space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
